Stock listing
NYSE American:KAPA Kairos Pharma, Ltd. Stock
Home listing (NYSE American) of Kairos Pharma, Ltd.
Follow Kairos Pharma, Ltd. into a list and get an email when it puts out news.
Share price · AMEX:KAPA
$0.436 USD -0.004 (-1.0%)
Close on Nov 20, 2026
- Day range
- $0.410 – $0.473 USDNov 20, 2026
- Volume
- 33,061 sharesNov 20, 2026
- Market cap
- $1.48M USDAt the close on Nov 20, 2026 · price × 3.39M shares outstanding
- 52-week range
- $0.381 – $7.280 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $374,614 USDMedian day 64,961 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NYSE American:KAPA · Home | $0.436 USD | -0.004 (-1.0%) | 33,061 | $0.473 | $0.473 | $0.410 | $0.440 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · AMEX:KAPA · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $0.436 | -0.004 | -1.0% | $0.473 | $0.473 | $0.410 | 33,061 | |
| $0.440 | +0.040 | +10.1% | $0.400 | $0.540 | $0.400 | 119,853 | |
| $0.400 | -0.007 | -1.7% | $0.407 | $0.408 | $0.381 | 20,498 | |
| $0.407 | -0.047 | -10.3% | $0.424 | $0.454 | $0.407 | 12,719 | |
| $0.454 | -0.027 | -5.6% | $0.500 | $0.500 | $0.453 | 12,521 | |
| $0.481 | -0.029 | -5.7% | $0.503 | $0.510 | $0.480 | 30,953 | |
| $0.510 | +0.036 | +7.6% | $0.500 | $0.510 | $0.474 | 20,226 | |
| $0.474 | -0.031 | -6.1% | $0.510 | $0.519 | $0.471 | 82,392 | |
| $0.505 | +0.017 | +3.5% | $0.489 | $0.530 | $0.489 | 34,789 | |
| $0.488 | +0.033 | +7.3% | $0.494 | $0.495 | $0.482 | 26,761 | |
| $0.455 | -0.035 | -7.2% | $0.520 | $0.520 | $0.424 | 72,813 | |
| $0.490 | -0.015 | -3.0% | $0.510 | $0.530 | $0.490 | 43,613 | |
| $0.505 | +0.032 | +6.7% | $0.470 | $0.505 | $0.418 | 195,423 | |
| $0.474 | -0.057 | -10.7% | $0.541 | $0.541 | $0.474 | 94,170 | |
| $0.530 | -0.010 | -1.9% | $0.540 | $0.550 | $0.525 | 47,378 | |
| $0.540 | +0.017 | +3.2% | $0.536 | $0.576 | $0.525 | 116,415 | |
| $0.523 | -0.007 | -1.3% | $0.543 | $0.560 | $0.523 | 64,961 | |
| $0.530 | -0.006 | -1.1% | $0.525 | $0.553 | $0.525 | 33,960 | |
| $0.536 | -0.023 | -4.1% | $0.571 | $0.580 | $0.536 | 66,398 | |
| $0.559 | +0.015 | +2.8% | $0.544 | $0.590 | $0.530 | 112,300 | |
| $0.544 | -0.033 | -5.7% | $0.585 | $0.600 | $0.543 | 83,000 | |
| $0.577 | -0.007 | -1.2% | $0.566 | $0.617 | $0.565 | 164,100 | |
| $0.584 | +0.014 | +2.5% | $0.558 | $0.603 | $0.530 | 153,500 | |
| $0.570 | -0.031 | -5.2% | $0.624 | $0.628 | $0.522 | 233,800 | |
| $0.601 | -0.070 | -10.4% | $0.692 | $0.692 | $0.601 | 134,400 | |
| $0.671 | -0.072 | -9.7% | $0.721 | $0.731 | $0.656 | 253,200 | |
| $0.743 | -0.086 | -10.4% | $0.804 | $0.804 | $0.711 | 285,500 | |
| $0.829 | -0.003 | -0.4% | $0.832 | $0.839 | $0.783 | 155,300 | |
| $0.832 | +0.022 | +2.7% | $0.815 | $0.839 | $0.740 | 251,000 | |
| $0.810 | -0.150 | -15.6% | $0.911 | $1.004 | $0.783 | 637,800 | |
| $0.960 | +0.090 | +10.3% | $0.930 | $1.250 | $0.915 | 5,820,700 | |
| $0.870 | -0.280 | -24.3% | $1.090 | $1.140 | $0.848 | 1,098,900 | |
| $1.150 | -0.400 | -25.8% | $1.590 | $2.160 | $1.060 | 9,944,600 | |
| $1.550 | -0.010 | -0.6% | $1.550 | $1.590 | $1.520 | 19,100 | |
| $1.560 | 0.000 | 0.0% | $1.610 | $1.620 | $1.535 | 25,800 | |
| $1.560 | -0.080 | -4.9% | $1.590 | $1.650 | $1.470 | 79,100 | |
| $1.640 | -0.020 | -1.2% | $1.710 | $1.780 | $1.600 | 99,300 | |
| $1.660 | -0.020 | -1.2% | $1.680 | $1.755 | $1.640 | 50,900 | |
| $1.680 | -0.040 | -2.3% | $1.740 | $1.798 | $1.650 | 51,800 | |
| $1.720 | -0.050 | -2.8% | $1.770 | $1.780 | $1.720 | 42,300 | |
| $1.770 | +0.040 | +2.3% | $1.700 | $1.820 | $1.695 | 299,900 | |
| $1.730 | -0.050 | -2.8% | $1.750 | $1.778 | $1.700 | 63,400 | |
| $1.780 | -0.010 | -0.6% | $1.780 | $1.810 | $1.700 | 247,100 | |
| $1.790 | +0.060 | +3.5% | $1.750 | $1.800 | $1.700 | 126,400 | |
| $1.730 | -0.080 | -4.4% | $1.810 | $1.840 | $1.720 | 168,700 | |
| $1.810 | 0.000 | 0.0% | $1.840 | $1.840 | $1.780 | 33,400 | |
| $1.810 | -0.040 | -2.2% | $1.840 | $1.840 | $1.810 | 5,300 | |
| $1.850 | +0.010 | +0.5% | $1.790 | $1.890 | $1.760 | 37,600 | |
| $1.840 | +0.082 | +4.7% | $1.700 | $1.860 | $1.700 | 53,500 | |
| $1.758 | +0.078 | +4.6% | $1.687 | $1.765 | $1.670 | 33,000 | |
| $1.680 | +0.020 | +1.2% | $1.690 | $1.730 | $1.621 | 32,600 | |
| $1.660 | -0.110 | -6.2% | $1.760 | $1.800 | $1.660 | 81,400 | |
| $1.770 | -0.070 | -3.8% | $1.850 | $1.890 | $1.770 | 173,400 | |
| $1.840 | +0.170 | +10.2% | $1.670 | $1.910 | $1.660 | 302,400 | |
| $1.670 | +0.090 | +5.7% | $1.550 | $1.690 | $1.550 | 47,600 | |
| $1.580 | -0.070 | -4.2% | $1.610 | $1.650 | $1.510 | 105,300 | |
| $1.650 | -0.030 | -1.8% | $1.720 | $1.850 | $1.520 | 76,300 | |
| $1.680 | +0.021 | +1.3% | $1.687 | $1.750 | $1.638 | 7,559 | |
| $1.659 | -0.028 | -1.7% | $1.708 | $1.743 | $1.624 | 4,543 | |
| $1.687 | -0.133 | -7.3% | $1.883 | $1.883 | $1.575 | 8,967 | |
| $1.820 | +0.084 | +4.8% | $1.764 | $1.897 | $1.729 | 13,694 | |
| $1.736 | +0.112 | +6.9% | $1.701 | $1.750 | $1.638 | 7,292 | |
| $1.624 | -0.406 | -20.0% | $1.806 | $1.806 | $1.540 | 35,200 | |
| $2.030 | -0.035 | -1.7% | $2.030 | $2.107 | $2.023 | 6,073 | |
| $2.065 | -0.105 | -4.8% | $2.163 | $2.240 | $2.044 | 5,073 |
Splits
1 split · AMEX:KAPA · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-7 | Consolidation |
- Ticker
- NYSE American:KAPA
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NYSE American
- Currency
- USD
What changed lately
Latest news release · Nov 5, 2026
Kairos Pharma Recognized by Biotech Breakthrough Awards in Oncology
Latest deck · Nov 3, 2026
Technical Presentation (November 2026)
Technical · 22 slides
Latest news
Kairos Pharma Recognized by Biotech Breakthrough Awards in Oncology
Nov 5, 2026
Closed $0.455 (-7.2%) on Nov 5, 2026
Kairos Pharma Presents at United Scientific Group’s 11th International Conference on Cancer Research & Drug Development
Nov 3, 2026
Closed $0.505 (+6.7%) on Nov 3, 2026
Kairos Pharma Reports Positive, Statistically Significant Interim Efficacy Data from Phase 2 Trial of ENV-105 in Metastatic Prostate Cancer
Oct 6, 2026
Closed $1.15 (-25.8%) on Oct 6, 2026
Kairos Pharma to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Sep 9, 2026
Closed $1.66 (-6.2%) on Sep 9, 2026
Kairos Pharma Announces 1-for-7 Reverse Stock Split
Aug 21, 2026
Closed $1.62 (-20.0%) on Aug 24, 2026
Kairos Pharma Announces Strategic Collaboration with Bayer to Enhance XOFIGO Activity in Metastatic Prostate Cancer
Jul 22, 2026
Closed $2.19 (-12.6%) on Jul 22, 2026
Kairos Pharma Reports Breakthrough Interim Safety Data in Phase 1 Trial of ENV-105 in EGFR-Mutated Lung Cancer Patients — Targeting a $10 Billion Drug Resistance Market
Jul 15, 2026
Closed $2.23 (-6.5%) on Jul 15, 2026
Kairos Pharma Recaps Important Acquisitions and Details Plans for the Balance of 2026 in Letter to Shareholders
Jun 4, 2026
Closed $3.26 (+0.9%) on Jun 4, 2026
Kairos Pharma Receives GHP Magazine’s Healthcare & Pharmaceutical Award
May 14, 2026
Closed $3.44 (+6.0%) on May 14, 2026
Kairos Pharma, Ltd. to Present at the LD Micro Invitational XVI
May 13, 2026
Closed $3.25 (-4.3%) on May 13, 2026
Kairos Pharma, Ltd. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 16 in the last 12 months · 30 in all · newest Nov 5, 2026 · oldest 2025
- Decks
- 7 decks · latest Nov 3, 2026
Where Kairos Pharma, Ltd. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NYSE American:KAPA · Home listing · This page | NYSE American | United States | USD |
| BOATS:KAPA | BOATS | United States | USD |
Valuation
Price/book 0.4× against a median of 0.2×: 6th lowest of 8 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- −$1.65M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- No depreciation figure on 6ix yet
- Price/book
- 0.4×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 1.36
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Kairos Pharma, Ltd. · AMEX:KAPA | US$1.48M | −US$1.65M | n/a | n/a | n/a | 0.4× | n/a | 0.0× | 1.36 |
| SOHM, Inc. · OTC:SHMN | US$1.74M | US$4.99M | n/a | 5.5× | n/a | 0.5× | −28.1% | 0.9× | -0.10 |
| PRF Technologies Ltd. · NASDAQ:PRFX | US$1.66M | −US$9.82M | n/a | −249× | n/a | 0.1× | n/a | 0.0× | 1.93 |
| Jupiter Neurosciences, Inc. · NASDAQ:JUNS | US$1.63M | US$1.33M | n/a | 16.9× | n/a | n/a | n/a | n/a | 1.88 |
| BioRestorative Therapies, Inc. · NASDAQ:BRTX | US$1.45M | −US$2.11M | n/a | −5.9× | n/a | 0.5× | n/a | 0.0× | 1.81 |
| Nutra Pharma Corp. · OTC:NPHC | US$1.43M | US$13.99M | n/a | 87.0× | n/a | n/a | n/a | n/a | n/a |
| Aptevo Therapeutics Inc. · NASDAQ:APVO | US$1.40M | −US$2.88M | n/a | n/a | n/a | 0.4× | n/a | 1.0× | 0.93 |
| Agentix Corp. · OTC:AGTX | US$1.35M | US$1.34M | n/a | n/a | n/a | n/a | n/a | n/a | -0.73 |
| Clearmind Medicine Inc. · NASDAQ:CMND | US$1.33M | −US$9.01M | n/a | n/a | n/a | 0.2× | n/a | 0.0× | 0.29 |
| Artelo Biosciences, Inc. · NASDAQ:ARTL | US$1.30M | US$1.34M | n/a | n/a | n/a | 0.2× | n/a | 0.0× | 1.36 |
| International Stem Cell Corporation · OTC:ISCO | US$1.28M | −US$18.76M | 0.1× | −2.0× | n/a | 0.1× | 222.6% | 0.0× | -0.52 |
| Median of the others | US$1.42M | −US$390,481 | 0.1× | 1.7× | 0.2× | 97.3% | 0.0× | 0.93 |
Forecasts
1 strong buy · 2 buy · Analysts' consensus from EODHD, read Nov 16, 2026. Not 6ix's view and not investment advice.
- Price target
- 49.00 USD · Analysts' mean
- EPS, year to Dec 2026
- -2.59 · 1 analyst
Team and board
Officers
| Officer | Role |
|---|---|
| John S. Yu | CEO & Chairman |
| Doug Samuelson | Chief Financial Officer |
| Ramchandran Murali | VP, Research and Development |
| Neil Bhowmick | Chief Scientific Officer |
Board
| Director | Role |
|---|---|
| John S. Yu | CEO & Chairman |
| Hyun W. Bae | |
| Michael Keyoung | |
| Rahul Singvhi |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 13, 2026 · After close | −10.3% |
| Q2 2026 | Aug 12, 2026 · After close | +1.4% |
| Q1 2026 | Jun 3, 2026 | −0.4% |
| Q4 2025 | Mar 31, 2026 · After close | +3.6% |
| Q3 2025 | Nov 14, 2025 · After close | −6.4% |
| Q2 2025 | Aug 12, 2025 · After close | −4.5% |
| Q1 2025 | Apr 15, 2025 · After close | −7.8% |
| Q4 2024 | Feb 26, 2025 | +6.1% |
| Q3 2024 | Nov 14, 2024 · After close | −24.6% |
| Q2 2024 | Aug 28, 2024 |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Technical Presentation (November 2026) | Technical | 22 slides | Nov 3, 2026 |
| Investor Presentation (September 2026) | Investor deck | 25 slides | Sep 14, 2026 |
| Investor Presentation (May 2026) | Investor deck | 32 slides | May 18, 2026 |
| Investor Presentation (2026) | Investor deck | 25 slides | 2026 |
| Corporate Update (September 2025) | Corporate update | 7 slides | Sep 18, 2025 |
| Investor Presentation (March 2025) | Investor deck | 24 slides | March 2025 |
| Investor Presentation (October 2024) | Investor deck | 25 slides | Oct 10, 2024 |
IPO
Priced at US$4.00 a share on Sep 16, 2024.
- Price
- US$4.00 a share
- Shares offered
- 1,550,000 shares of common stock
- Offering size
- US$6.2 million
- Underwriters' option
- Up to 232,500 more shares
- Listing
- KAPA on NYSE American
- Underwriters
- Boustead Securities, LLC, EF Hutton LLC, Sutter Securities, Inc. · In the order on the cover
- Shares delivered
- On or about Sep 17, 2024
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Mar 29, 2023 |
| Filed publicly | Sep 29, 2023 |
| Amended 8 times | Newest Aug 16, 2024 |
| Shares registered with an exchange | Sep 12, 2024 |
| Declared effective by the SEC | Sep 16, 2024 |
| Final prospectus, with the price | Sep 17, 2024 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Sep 17, 2024 |
| EFFECT · Notice that a registration is effective | Sep 16, 2024 |
| CORRESP · Letter to the SEC | Sep 13, 2024 |
| CORRESP · Letter to the SEC | Sep 13, 2024 |
| CORRESP · Letter to the SEC | Sep 13, 2024 |
| CERT · Exchange's certificate of listing | Sep 12, 2024 |
| 8-A12B · Registration of shares for listing on an exchange | Sep 12, 2024 |
| CORRESP · Letter to the SEC | Sep 9, 2024 |
| CORRESP · Letter to the SEC | Sep 9, 2024 |
| S-1/A · Registration statement, amended | Aug 16, 2024 |
All 27 filings
| Filing | Filed |
|---|---|
| S-1/A · Registration statement, amended | Jun 4, 2024 |
| CORRESP · Letter to the SEC | Jun 3, 2024 |
| S-1/A · Registration statement, amended | May 24, 2024 |
| S-1/A · Registration statement, amended | May 20, 2024 |
| S-1/A · Registration statement, amended | May 13, 2024 |
| S-1/A · Registration statement, amended | May 1, 2024 |
| S-1/A · Registration statement, amended | Feb 14, 2024 |
| S-1/A · Registration statement, amended | Dec 7, 2023 |
| S-1 · Registration statement | Sep 29, 2023 |
| DRS/A · Draft registration statement, amended | Sep 18, 2023 |
| DRSLTR · Letter to the SEC with a draft | Sep 15, 2023 |
| UPLOAD · Letter from the SEC | Jul 6, 2023 |
| DRSLTR · Letter to the SEC with a draft | Jun 28, 2023 |
| DRS/A · Draft registration statement, amended | Jun 28, 2023 |
| DRS/A · Draft registration statement, amended | Jun 28, 2023 |
| UPLOAD · Letter from the SEC | Apr 25, 2023 |
| DRS · Draft registration statement | Mar 29, 2023 |
Open IPO · From the cover of the final prospectus (424B4) filed Sep 17, 2024
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of revenue | 160.0K | 160.0K | 160.0K | 98.0K | ||
| Gross profit | -160.0K | -160.0K | -160.0K | -98.0K | ||
| Research and development | 2.13M | 414.0K | 82.0K | 87.0K | 183.0K | 20.0K |
| Selling, general and administrative | 3.44M | 1.93M | 1.47M | 324.0K | 1.66M | 1.03M |
| Operating income | -5.57M | -2.34M | -1.71M | -571.0K | -1.94M | -1.05M |
| Depreciation and amortization | 160.0K | 160.0K | 160.0K | 160.0K | 98.0K | 0 |
| EBITDA | -5.41M | -2.18M | -1.55M | -411.0K | -1.84M | -1.05M |
| Interest expense | 0 | 35.0K | 42.0K | 479.0K | 202.0K | 5.41K |
| Income before tax | -5.45M | -2.60M | -1.81M | -1.05M | -2.15M | -1.05M |
| Income tax | -2.60M | |||||
| Net income | -5.45M | -2.60M | -1.81M | -1.05M | -2.15M | -1.05M |
| Earnings per share, basic | -0.30 | -0.23 | -0.17 | -0.72 | -1.17 | -0.66 |
| Earnings per share, diluted | -0.30 | -0.23 | -0.17 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Cash and equivalents | 4.49M | 1.27M | 93.0K | 437.0K | 73.0K | 14.3K |
| Current assets | 5.39M | 4.17M | 101.0K | 437.0K | 73.0K | 14.3K |
| Total assets | 6.54M | 5.77M | 965.0K | 1.04M | 775.0K | 14.3K |
| Accounts payable | 199.0K | 992.0K | 2.40M | 1.63M | 1.55M | 307.1K |
| Current liabilities | 199.0K | 992.0K | 2.40M | 1.63M | 1.94M | 357.1K |
| Long-term debt | 638.0K | 582.0K | ||||
| Total debt | 638.0K | 586.0K | 380.0K | 50.0K | ||
| Total liabilities | 199.0K | 992.0K | 3.04M | 2.21M | 1.94M | 357.1K |
| Shareholders' equity | 6.34M | 4.78M | -2.08M | -1.18M | -1.17M | -342.8K |
| Shares outstanding | 2.97M | 13.7M | 10.6M | 1.46M | 1.83M | 1.60M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Cash from operations | -3.44M | -3.96M | 81.0K | -353.0K | -412.0K | -38.5K |
| Capital spending | 0 | 0 | 0 | 0 | 0 | -5 |
| Free cash flow | -3.44M | -3.96M | 81.0K | -353.0K | -412.0K | -38.5K |
| Cash from investing | -109.0K | |||||
| Cash from financing | 6.66M | 5.13M | -425.0K | 717.0K | 580.0K | 37.0K |
| Change in cash | 3.22M | 1.18M | -344.0K | 364.0K | 59.0K | -1.53K |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| PRE 14A · Preliminary proxy statement | Nov 20, 2026 | Meeting notice | SEC |
| 10-Q · Quarterly report | Nov 13, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 5, 2026 | Current report | SEC |
| 8-K · Current report | Nov 3, 2026 | Material contract | SEC |
| 8-K · Current report | Oct 6, 2026 | Current report | SEC |
| 8-K · Current report | Sep 14, 2026 | Current report | SEC |
| 8-K · Current report | Aug 21, 2026 | Current report | SEC |
| 10-Q · Quarterly report | Aug 12, 2026 | Quarterly report | SEC |
| 8-K · Current report | Jul 22, 2026 | Material contract | SEC |
| 8-K · Current report | Jul 15, 2026 | Current report | SEC |
All 127 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 8-K · Current report | Jun 30, 2026 | Meeting outcome | SEC |
| 8-K · Current report | Jun 4, 2026 | Current report | SEC |
| DEFA14A · Additional proxy material | May 26, 2026 | Meeting notice | SEC |
| ARS · Annual report to shareholders | May 22, 2026 | Annual report | SEC |
| DEF 14A · Proxy statement | May 22, 2026 | Meeting notice | SEC |
| 8-K · Current report | May 18, 2026 | Current report | SEC |
| 10-Q · Quarterly report | May 13, 2026 | Quarterly report | SEC |
| PRE 14A · Preliminary proxy statement | May 11, 2026 | Meeting notice | SEC |
| 424B3 · Prospectus | Apr 1, 2026 | Offer document | SEC |
| 424B3 · Prospectus | Apr 1, 2026 | Offer document | SEC |
| 10-K · Annual report | Mar 31, 2026 | Annual report | SEC |
| 8-K · Current report | Mar 2, 2026 | Material contract | SEC |
| 8-K · Current report | Feb 26, 2026 | Current report | SEC |
| EFFECT · Notice that a registration is effective | Jan 26, 2026 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jan 21, 2026 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Jan 15, 2026 | Other filings | SEC |
| S-3 · Registration statement | Jan 12, 2026 | Offer document | SEC |
| 4 · Change in ownership | Dec 30, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 26, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 26, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 26, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 26, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 26, 2025 | Insider trade | SEC |
| 10-Q · Quarterly report | Nov 14, 2025 | Quarterly report | SEC |
| 8-K · Current report | Oct 15, 2025 | Management or board change | SEC |
| 8-K · Current report | Oct 7, 2025 | Material contract | SEC |
| 8-K · Current report | Sep 18, 2025 | Current report | SEC |
| 8-K · Current report | Sep 11, 2025 | Current report | SEC |
| 8-K · Current report | Sep 3, 2025 | Current report | SEC |
| 424B3 · Prospectus | Aug 19, 2025 | Offer document | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 12, 2025 | Quarterly report | SEC |
| 10-K/A · Annual report, amended | Jul 28, 2025 | Annual report | SEC |
| 8-K · Current report | Jul 15, 2025 | Current report | SEC |
| 8-K · Current report | Jun 12, 2025 | Material contract | SEC |
| 8-K · Current report | Jun 3, 2025 | Current report | SEC |
| DEFR14A | May 16, 2025 | Meeting notice | SEC |
| SCHEDULE 13G · Big-stake notice | May 15, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 14, 2025 | Quarterly report | SEC |
| PRER14A | May 6, 2025 | Other filings | SEC |
| DEF 14A · Proxy statement | Apr 30, 2025 | Meeting notice | SEC |
| 3 · Initial statement of ownership | Apr 30, 2025 | Insider trade | SEC |
| 10-K/A · Annual report, amended | Apr 28, 2025 | Annual report | SEC |
| 8-K · Current report | Apr 28, 2025 | Current report | SEC |
| 424B3 · Prospectus | Apr 25, 2025 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Apr 25, 2025 | Other filings | SEC |
| 8-K · Current report | Apr 24, 2025 | Current report | SEC |
| CORRESP · Letter to the SEC | Apr 22, 2025 | Other filings | SEC |
| S-1 · Registration statement | Apr 21, 2025 | Offer document | SEC |
| 10-K · Annual report | Apr 15, 2025 | Annual report | SEC |
| 4 · Change in ownership | Apr 7, 2025 | Insider trade | SEC |
| NT 10-K · Late filing notice | Mar 28, 2025 | Explanation request | SEC |
| 8-K · Current report | Mar 20, 2025 | Current report | SEC |
| 8-K · Current report | Feb 26, 2025 | Current report | SEC |
| 4 · Change in ownership | Feb 24, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 24, 2025 | Insider trade | SEC |
| DEF 14C | Feb 10, 2025 | Meeting notice | SEC |
| 8-K · Current report | Feb 6, 2025 | Current report | SEC |
| 424B3 · Prospectus | Feb 5, 2025 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Feb 5, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jan 31, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Jan 31, 2025 | Other filings | SEC |
| PRE 14C | Jan 29, 2025 | Meeting notice | SEC |
| S-1 · Registration statement | Jan 29, 2025 | Offer document | SEC |
| D | Jan 28, 2025 | Other filings | SEC |
| 8-K · Current report | Jan 17, 2025 | Material contract | SEC |
| 8-K · Current report | Jan 14, 2025 | Material contract | SEC |
| UPLOAD · Letter from the SEC | Jan 6, 2025 | Other filings | SEC |
| DRS · Draft registration statement | Jan 3, 2025 | Offer document | SEC |
| 8-K · Current report | Dec 13, 2024 | Management or board change | SEC |
| 4 · Change in ownership | Nov 25, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 25, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 21, 2024 | Insider trade | SEC |
| 8-K · Current report | Nov 19, 2024 | Current report | SEC |
| 10-Q · Quarterly report | Nov 14, 2024 | Quarterly report | SEC |
| 8-K · Current report | Oct 10, 2024 | Current report | SEC |
| 8-K · Current report | Oct 4, 2024 | Material contract | SEC |
| S-8 · Registration statement for employee plans | Sep 27, 2024 | Offer document | SEC |
| 8-K · Current report | Sep 27, 2024 | Material contract | SEC |
| 3 · Initial statement of ownership | Sep 24, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Sep 24, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Sep 24, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Sep 24, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Sep 24, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Sep 24, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Sep 24, 2024 | Insider trade | SEC |
| 8-K · Current report | Sep 24, 2024 | Material contract | SEC |
| 8-K · Current report | Sep 17, 2024 | Material contract | SEC |
| 424B4 · Prospectus | Sep 17, 2024 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Sep 17, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Sep 13, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Sep 13, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Sep 13, 2024 | Other filings | SEC |
| CERT · Exchange's certificate of listing | Sep 12, 2024 | Other filings | SEC |
| 8-A12B · Registration of shares for listing on an exchange | Sep 12, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Sep 9, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Sep 9, 2024 | Other filings | SEC |
| S-1/A · Registration statement, amended | Aug 16, 2024 | Offer document | SEC |
| CORRESP · Letter to the SEC | Jun 3, 2024 | Other filings | SEC |
| S-1/A · Registration statement, amended | Jun 3, 2024 | Offer document | SEC |
| S-1/A · Registration statement, amended | May 24, 2024 | Offer document | SEC |
| S-1/A · Registration statement, amended | May 20, 2024 | Offer document | SEC |
| S-1/A · Registration statement, amended | May 10, 2024 | Offer document | SEC |
| S-1/A · Registration statement, amended | Apr 30, 2024 | Offer document | SEC |
| S-1/A · Registration statement, amended | Feb 14, 2024 | Offer document | SEC |
| S-1/A · Registration statement, amended | Dec 6, 2023 | Offer document | SEC |
| S-1 · Registration statement | Sep 29, 2023 | Offer document | SEC |
| DRSLTR · Letter to the SEC with a draft | Sep 15, 2023 | Other filings | SEC |
| DRS/A · Draft registration statement, amended | Sep 15, 2023 | Offer document | SEC |
| UPLOAD · Letter from the SEC | Jul 6, 2023 | Other filings | SEC |
| DRSLTR · Letter to the SEC with a draft | Jun 28, 2023 | Other filings | SEC |
| DRS/A · Draft registration statement, amended | Jun 28, 2023 | Offer document | SEC |
| DRS/A · Draft registration statement, amended | Jun 28, 2023 | Offer document | SEC |
| D | Apr 26, 2023 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Apr 25, 2023 | Other filings | SEC |
| DRS · Draft registration statement | Mar 28, 2023 | Offer document | SEC |
Cap table
Built by 6ix from Kairos Pharma, Ltd.’s releases
- Common shares
- 3,385,383
- Fully diluted
- 3,385,383
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 3,385,383 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 3,385,383 |
| Aug 21, 2026 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Hansoo Michael Keyoung Other companies: CalciMedica, Inc. (Director · Sep 24, 2020 – Sep 29, 2020 · Past) | Director · Since at least Sep 16, 2024 |
| Rahul Singhvi Other companies: Codexis, Inc. (Director · Since at least Sep 28, 2022) | Director · Since at least Dec 10, 2024 |
| Doug Samuelson | Chief Financial Officer · Since at least Nov 4, 2026 |
| Hyun W. Bae | Director · Since at least Sep 16, 2024 |
| John S. Yu | CEO & Chairman · Since at least Oct 6, 2026 |
| Louie Toma | Investor Relations · May 6, 2025 – Nov 4, 2026 · Past |
| Michael Keyoung | Director · Since at least Nov 5, 2026 |
| Neil Bhowmick | Chief Scientific Officer · Since at least Nov 3, 2026 |
| Rahul Singvhi | Director · Since at least Nov 5, 2026 |
| Ramachandran Murali | VP of Research and Development · Since at least Oct 8, 2025 |
All 11 people
| Person | Seat |
|---|---|
| Ramchandran Murali | VP, Research and Development · Since at least Nov 4, 2026 |
Log in to ask 6ix AI your own questions about Kairos Pharma, Ltd.